ArticleOncotarget2018

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Guillemette Fouquet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.